

June 28, 2021

The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai 400 023
Fax No. 2272 5092/3030

Ref. Scrip code: 539680

Sub.: Outcome of the Board Meeting held today i.e. on June 28, 2021

Dear Sir,

With regard to the captioned subject and in compliance with the Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., on June 28, 2021 (commenced at 2.30 p.m. and concluded at 3.00 p.m.) have inter-alia considered and approved;

1. Audited Financial results for the half and financial year ended on March 31, 2021, in this regard, please find enclosed herewith:
 - (a) Audited Financial Results of the Company for the half and financial year ended on March 31, 2021.
 - (b) Auditor's Report in respect of the Audited Financial Results of the Company for the financial year ended March 31, 2021.


These are also being made available on the website of the Company at www.ayurvedganga.com.


Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company have issued their audit reports with unmodified opinion for the half and financial year ended on March 31, 2021.

Please take the same on your records and suitably disseminated at all concerned.

Thanking you,

Yours faithfully,
For Ganga Pharmaceuticals Limited


Bharat Sharma
Managing Director
DIN: 00077026
Email ID: bharat.sharma@gangapharma.in



Anil Bansal & Associates

— CHARTERED ACCOUNTANTS —

Independent Auditor's Report on Financial Results of Ganga Pharmaceuticals Limited for the half and year ended 31st March, 2021 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

TO

THE BOARD OF DIRECTORS OF GANGA PHARMACEUTICALS LIMITED

Report on the audit of the Financial Results

Opinion

We have audited the accompanying Financial results of Ganga Pharmaceuticals Limited (hereinafter referred to as the "Company") for the half and year ended 31st March, 2021, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Annual Financial Results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other financial information for the half year and year ended 31st March, 2021.

Basis for Opinion


We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the Financial Results.

Reg. Office: 1001, IJMIMA Complex, Raheja's Metroplex, Link Road, Malad (West), Mumbai - 400064.

Phone: 022 - 49795471

E-mail: info@caanilbansal.com / anilbansal1001@gmail.com

Website: www.caanilbansal.com



Anil Bansal & Associates

— CHARTERED ACCOUNTANTS —

Emphasis of Matter

We draw your attention to note 2 to the financial results which explain the uncertainties and the management's assessment of the financial impact due to the lock-downs and other restrictions and conditions related to COVID-19 pandemic situation, for which definitive assessment of the impact in the subsequent period is dependent upon circumstances as they evolve. Our opinion is not modified in respect of this matter.

Management's and Board of Directors' Responsibilities for the Annual Financial Results

These half yearly and yearly annual financial results have been prepared on the basis of the interim and annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error

In preparing the annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's

Reg. Office: 1001, IJMIMA Complex, Raheja's Metroplex, Link Road, Malad (West), Mumbai - 400064.

Phone: 022 - 49795471

E-mail: info@caanilbansal.com / anilbansal1001@gmail.com

Website: www.caanilbansal.com



Anil Bansal & Associates

— CHARTERED ACCOUNTANTS —

report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual financial results, including the disclosures, and whether the annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Reg. Office: 1001, IJMIMA Complex, Raheja's Metroplex, Link Road, Malad (West), Mumbai - 400064.

Phone: 022 - 49795471

E-mail: info@caanilbansal.com / anilbansal1001@gmail.com

Website: www.caanilbansal.com



Anil Bansal & Associates


— CHARTERED ACCOUNTANTS —

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


Other Matters

The Annual Financial Results include the results for the half year ended 31st March, 2021 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the first half of the current financial year which were subject to limited review by us.

For Anil Bansal & Associates
Chartered Accountants
Firm Registration No. 100421W


Anil Bansal
Partner

Membership No.: 043918
UDIN: 21043918AAAADF7072
Place: Mumbai
Date: 28th June, 2021



Reg. Office: 1001, IJMIMA Complex, Raheja's Metroplex, Link Road, Malad (West), Mumbai - 400064.

Phone: 022 - 49795471

E-mail: info@caanilbansal.com / anilbansal1001@gmail.com

Website: www.caanilbansal.com

Statement of Audited Consolidated Financial Results for the Half and Year ended March 31,2021					
Rs.in Lacs					
Sr. No	Particulars	Figures for the half year ended on			Financial year ended on
		31-03-2021	30/09/2020	31/03/2020	31-03-2021
		(Audited)	(Un-Audited)	(Audited)	(Audited)
1	INCOME FROM OPERATIONS				
	(a) Revenue from operations	122.96	114.48	169.64	237.44
	(b) Other Income	18.70	6.73	9.01	25.43
	Total Income	141.66	121.21	178.66	262.86
2	Expenses:				
	(a) Cost of Materials consumed	94.57	47.57	52.09	142.14
	(b) Purchase of stock in trade				-
	(c) Change in inventories of finished goods & packing Material	(26.42)	7.94	8.30	(18.48)
	(d) Employee Benefit Expenses	16.79	26.02	29.35	42.81
	(e) Finance Cost	9.95	9.47	12.05	19.42
	(f) Depreciation and Amortization Expense	2.69	2.68	2.82	5.37
	(g) Other Administrative Expenses	42.52	25.35	69.52	67.86
	Total Expenses	140.10	119.03	174.13	259.12
3	Profit /(Loss) before Tax (1-2)	1.56	2.18	4.53	3.74
4	Tax Expenses				
	(a) Current Tax	0.26	0.57	1.03	0.83
=	(b) Deffered Tax	0.18	(0.04)	0.14	0.14
	(C) Earlier tax	0.73	-	-	0.73
5	Net Profit / (Loss) for the period (3-4)	0.39	1.65	3.36	2.04
6	Other Comprehensive Income				
7	Paid - Up equity share capital (Equity Share of Rs. 10/- each)	406.15	406.15	406.15	406.15
8	Earning per equity share (Rs.)				
	(1) Basic	0.01	0.04	0.08	0.05
	(2) Diluted	0.01	0.04	0.08	0.05

Note

- The above results for the half year ended 31-03-2021 have been reviewed by the Audit Committee in their meeting held on 28th June 2021 and approved by the Board of Directors in their meeting held on 28th June 2021.
- By mid of March 2020, novel corona virus (Covid-19) had spread across the world and since then the pandemic has severely affected publichealth and disrupted economic activities. In response to this pandemic, Governments across the world had to impose various restrictions including lockdowns and mandatory work from home requirements. This has affected the operations of the Company and has had impact on the sales and profitability amongst others. The Company is continuously monitoring the situation and taking necessary actions in response to the developments to minimise the impact and also to safeguard the assets and employees.
- Previous period's figures have been regrouped/reclassified wherever necessary.

For and on behalf of the Board of Directors
Ganga Pharmaceuticals Limited

Bharat Sharma
Managing Director
DIN : 00077026
Place: Virar, Palghar
Date : 28 June, 2021



GANGA PHARMACEUTICALS LTD

CIN: L99999MH1989PLC053392

Registered Office: Gangatat, Dhanvantari Marg, Gopcharpada, Virar (East), Palghar -401305
 Tele Nos.:0250-6098333/444 ; Website: www.ayurvedganga.com; Email id:gangapharmaltd@gmail.com

Statement of Audited Consolidated Assests and Liabilities as at 31st March 2021

	Statement of Assets and Liabilities Particulars	As at (31-03-2021)	As at (31-03-2020)
A	EQUITY AND LIABILITIES		
	(1) Shareholders Funds:		
	(a) Share Capital	406,15,000	406,15,000
	(b) Reserve & Surplus	131,14,083	129,10,545
	(2) Non-Current Liabilities		
	(a) Long-Term Borrowings	67,39,993	59,27,500
	(b) Deferred Tax Liabilities (Net)	71,680	57,249
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	(3) Current Liabilities		
	(a) Short-term borrowings	88,46,864	85,91,056
	(b) Trade payables		
	i) Total outsatndng dues of micro enterprises and small enterprises	1,69,709	13,55,720
	ii) Total outsatndng dues of creditors other then micro enterprises and small enterprises	42,35,351	42,10,758
	(c) Other current liabilities	27,27,044	19,81,630
	(d) Short-term provisions	82,805	21,582
	Total	766,02,530	756,71,040
B	ASSETS		
	(1) Non - Current assets		
	(a) Fixed Assets	72,09,085	75,78,167
	(b) Non-current investments	8,92,500	8,92,500
	(c) Deferred tax assets (net)	-	-
	(d) Long term loans and advances	-	-
	(e) Other Non-current assets	226,22,531	230,21,411
	(2) Current assets		
	(a) Current Investment	-	-
	(b) Inventories	113,28,747	103,95,750
	(c) Trade receivables	81,97,339	107,05,650
	(d) Cash and cash equivalents	1,45,125	1,16,730
	(e) Short-term loans and advances	146,42,523	122,79,870
	(f) Other current assets	115,64,680	106,80,962
	Total	766,02,530	756,71,040

For and on behalf of the Board of Directors
 Ganga Pharmaceuticals Limited

Bharat Sharma
 Managing Director
 DIN : 00077026



Place: Virar, Palghar
 Date : 28 June, 2021

GANGA PHARMACEUTICALS LIMITED

Cash Flow Statement for the year ended 31st March 2021

	31st March 2021 Rupees	31st March 2021 Rupees	31st March 2020 Rupees	31st March 2020 Rupees
A. Cash flow from operating activities:				
Net profit before tax as per Profit and Loss Account:		3,74,013		25,50,762
Adjustment to reconcile profit before tax to net cash flows :				
Depreciation and amortisation expense	5,36,925		5,41,669	
Interest on advance & deposit recd	(25,30,980)		(16,46,020)	
Finance cost	17,91,406		21,81,865	
Prior period Item	-		-	
		(2,02,649)		10,77,514
Operating profit before working capital changes		1,71,364		36,28,276
Movements in working capital:				
(Decrease) / Increase in trade payables	(11,61,418)		84,323	
(Decrease) / Increase in other liabilities	7,45,414		2,19,998	
(Decrease) / Increase in Short term	2,55,808		(35,15,978)	
(Increase) / Decrease in trade receivables	25,08,311		15,58,576	
(Increase) / Decrease in other current assets	(8,83,718)		(55,43,159)	
(Increase) / Decrease in Short-term loans and advances	(23,62,653)		(86,662)	
(Increase) / Decrease in Inventories	(9,32,997)		11,42,340	
		(18,31,252)		(61,40,562)
Cash generated from operations		(16,59,888)		(25,12,286)
Taxes paid		(94,820)		(5,51,758)
Net cash from operating activities		(17,54,708)		(30,64,044)
B. Cash flow from investing activities:				
Purchase of fixed assets	(1,67,843)		(1,01,115)	
Advances given	-		-	
Deposit made / matured during the year	3,98,880		21,47,964	
Investment made during the year	-		-	
Interest received	25,30,980		16,46,020	
Net cash used in investing activities		27,62,017		36,92,869



GANGA PHARMACEUTICALS LIMITED
Cash Flow Statement (Contd.)

	31st March 2021 Rupees	31st March 2021 Rupees	31st March 2020 Rupees	31st March 2020 Rupees
C. Cash flow from financing activities:				
Repayment of borrowings	8,12,493		(6,95,588)	
Proceeds from borrowings	-		-	
Finance cost	(17,91,406)		(21,81,865)	
Net cash used in financing activities		(9,78,913)		(28,77,453)
Net increase / (Decrease) in cash and cash equivalents		28,396		(22,48,628)
Cash and cash equivalents as at the beginning of the year		1,16,729		23,65,357
Cash and cash equivalents as at the end of the year		1,45,125		1,16,729
Cash and cash equivalent comprises of :				
Cash in hand		1,16,933		1,96,085
Balance with banks		28,192		(79,355)
Total		1,45,125		1,16,730

Notes:

- 1 The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Notified Accounting Standard - 3 on Cash Flow Statements.
- 2 Figures in bracket indicate cash outgo.
- 3 Previous years' figures have been regrouped/rearranged to conform with current years' classifications.

As per our report of even date

**For and on behalf of the Board of Directors of
Ganga Pharmaceuticals Limited**

Bharat Sharma
Managing Director
DIN : 00077026



Place : Mumbai

Date : 28th June 2021